Asma Sassi, Xavier Peyrassol, Martina Marangoni, Alexander Gheldof, Sonia Van Dooren, Beatrice Alvaro Mercadal, Axelle Pintiaux, Caroline Antoine, Marc Abramowicz, Julie Désir, Anne Delbaere
{"title":"Exploring genetic variants in premature ovarian insufficiency: a cohort-based investigation of monogenic etiologies.","authors":"Asma Sassi, Xavier Peyrassol, Martina Marangoni, Alexander Gheldof, Sonia Van Dooren, Beatrice Alvaro Mercadal, Axelle Pintiaux, Caroline Antoine, Marc Abramowicz, Julie Désir, Anne Delbaere","doi":"10.1210/jendso/bvag215","DOIUrl":"https://doi.org/10.1210/jendso/bvag215","url":null,"abstract":"<p><strong>Context: </strong>Premature ovarian insufficiency (POI), affecting about 3.5% of women under 40, is marked by menstrual irregularities, amenorrhea, and heterogeneous pubertal development. Although next-generation sequencing (NGS) has expanded the list of POI-associated genes, most cases remain unexplained, and the clinical diagnostic value of gene panels is still insufficiently assessed.</p><p><strong>Objective: </strong>This study combines a cohort-based analysis with a critical methodological reassessment of NGS diagnostic yield in POI.</p><p><strong>Design: </strong>Prospective multicenter observational cohort study (2016-2023).</p><p><strong>Setting: </strong>Three Belgian academic hospitals.</p><p><strong>Patients: </strong>One hundred sixty unrelated women with idiopathic POI and 716 female controls.</p><p><strong>Intervention: </strong>Targeted NGS of 155 POI-associated genes. Variants were classified following American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines, and genes were evaluated using the latest gene-disease relationship (GDR) scoring framework.</p><p><strong>Main outcome measures: </strong>Identification of pathogenic/likely pathogenic (P/LP) variants (primary outcome). Diagnostic yield of the gene panel based on genes with strong evidence (secondary outcome).</p><p><strong>Results: </strong>Pathogenic/likely pathogenic variants were identified in 19.3% of patients; however, only 7.5% were considered clinically relevant based on gene validity and inheritance patterns. Limiting analysis to the 40 genes with the strongest GDR evidence yielded a 4.4% diagnostic rate. Adding 10 genes supported by recent literature increased the yield to 7.5%. In patients with primary amenorrhea, the diagnostic rate reached 15.4%. These findings highlight the gap between variant burden and true diagnostic yield in POI.</p><p><strong>Conclusion: </strong>Targeted NGS panels provide valuable clinical insight into POI genetics but should be complemented with broader genomic approaches for comprehensive diagnosis.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 11","pages":"bvag215"},"PeriodicalIF":4.4,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13714545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giada Rossi, Ida Pastore, Laura Montefusco, Lorenzo Pozzi Canova, Francesca D'Addio, Paolo Fiorina
{"title":"Six-month real-world glycemic improvement after Smart MDI system in type 1 diabetes.","authors":"Giada Rossi, Ida Pastore, Laura Montefusco, Lorenzo Pozzi Canova, Francesca D'Addio, Paolo Fiorina","doi":"10.1210/jendso/bvag244","DOIUrl":"https://doi.org/10.1210/jendso/bvag244","url":null,"abstract":"<p><strong>Background and aims: </strong>Smart multiple daily injection (Smart MDI) system integrating continuous glucose monitoring (CGM), insulin pens, and decision-support tools may optimize glycemic control in type 1 diabetes (T1D). However, real-world data remain limited. We evaluated 6-month glycemic outcomes following transition to Smart MDI in adults with T1D and explored differences according to carbohydrate counting status.</p><p><strong>Methods: </strong>This retrospective, single-center, observational study included 24 adults with T1D on MDI who transitioned to Smart MDI. CGM metrics were analyzed at baseline and after 1, 3, and 6 months. The primary outcome was change in time in range (TIR 70-180 mg/dL). Secondary outcomes included time above range (TAR), time below range (TBR), mean glucose, glucose management indicator (GMI), coefficient of variation, and HbA1c. Exploratory analyses compared individuals practicing carbohydrate counting (n = 12) with those who did not (n = 12).</p><p><strong>Results: </strong>TIR increased progressively from 56.1 ± 20.4% to 66.3 ± 17.5% (median change +9.0%, <i>P</i> < .01). TAR and TBR significantly decreased. HbA1c declined from 7.6 ± 1.1% to 7.3 ± 0.9% (median change -0.2%, <i>P</i> = .01). While between-group differences were not significant, individuals not practicing carbohydrate counting showed preliminary within-group improvements in TIR, TAR, mean glucose, GMI, and HbA1c, without increased TBR, whereas changes in the carbohydrate counting group were smaller.</p><p><strong>Conclusions: </strong>Transition to the Smart MDI system was associated with clinically meaningful improvements in CGM metrics and HbA1c over 6 months. Improvements among individuals not practicing carbohydrate counting suggest that the Smart MDI system may provide standardized decision support also beneficial in less structured self-management settings. Larger studies are warranted to confirm these findings.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 11","pages":"bvag244"},"PeriodicalIF":4.4,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13714543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149298286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giuseppe Seminara, Ettore D'Aleo, Marco Leuzzi, Maria Carmela Zagari, Emanuela A Greco, Antonio Aversa
{"title":"The lost scent of excitation: dissociation between cognitive desire and physical arousal in Kallmann syndrome.","authors":"Giuseppe Seminara, Ettore D'Aleo, Marco Leuzzi, Maria Carmela Zagari, Emanuela A Greco, Antonio Aversa","doi":"10.1210/jendso/bvag247","DOIUrl":"10.1210/jendso/bvag247","url":null,"abstract":"<p><p>Kallmann syndrome (KS) is a rare form of congenital hypogonadotropic hypogonadism (CHH) that causes delayed puberty and infertility, accompanied by a lifelong loss of smell. While hormone replacement therapy (HRT) restores standard hormone levels, the specific impact of an absent sense of smell on sexual relationships and desire remains largely unstudied. This study examined how lifelong smell loss shapes the psychosexual experiences of affected individuals. 38 adults were evaluated: 19 patients receiving stable HRT (10 with KS who lacked a sense of smell and 9 with CHH but normal smell) and 19 healthy matched individuals. Participants completed validated questionnaires assessing sexual desire, physical arousal, romantic behaviors, and attitudes toward intimacy. HRT effectively restored baseline sexual desire and general attitudes across all patients. However, individuals with KS reported significantly lower physical sexual arousal and engaged in far fewer sexual behaviors than those with an intact sense of smell. The lack of smell independently predicted lower arousal levels, despite patients maintaining normal mental desire and positive attitudes toward sex. These findings show that hormone therapy alone is insufficient to fully restore the sexual experience in KS. The lifelong absence of smell creates a distinct divide between mental desire and physical arousal, undermining sexual confidence and intimacy. Healthcare providers should therefore incorporate psychosexual counseling into routine clinical care to help patients navigate these sensory and emotional challenges.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 11","pages":"bvag247"},"PeriodicalIF":4.4,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Khaled Elhady Mohamed, Christian S Thudium, Asger Reinstrup Bihlet, Mette Sørensen Iken, Morten Asser Karsdal, Kim Henriksen, Anne-Christine Bay-Jensen
{"title":"Obesity-a key driver in osteoarthritis.","authors":"Khaled Elhady Mohamed, Christian S Thudium, Asger Reinstrup Bihlet, Mette Sørensen Iken, Morten Asser Karsdal, Kim Henriksen, Anne-Christine Bay-Jensen","doi":"10.1210/jendso/bvag245","DOIUrl":"10.1210/jendso/bvag245","url":null,"abstract":"<p><strong>Purpose: </strong>Obesity causes mechanical stress and metabolic dysfunction. However, the relationship between obesity and osteoarthritis (OA) pain still needs further investigation. This study aims to examine the effect of weight loss on pain and function through a secondary analysis of a randomized, double-blind, multicenter OA trial and to evaluate obesity's impact on OA pain using a rat model.</p><p><strong>Methods: </strong>In a post hoc analysis of a randomized controlled trial (RCT; NCT00486434), we evaluated baseline body mass index and Western Ontario and McMaster Universities Osteoarthritis (WOMAC) scores (<i>n</i> = 1175) and examined the impact of 5% weight loss on WOMAC scores after 2 years using a factorial analysis of covariance (<i>n</i> = 674). In a preclinical model of metabolic OA induced by meniscectomy, pain-like behavior was assessed with the von Frey and cold plate tests.</p><p><strong>Results: </strong>Participants who lost >5% of weight within 2 years experienced a mean decrease of -567.1 (95% CI -666.7 to -467.6) and -399.2 (-505.8 to -292.5) in total WOMAC scores for their target and nontarget knees, respectively, whereas individuals who gained >5% in weight had a smaller decrease of -364.6 (-496.5 to -232.7) and -135 (-277.4 to -6.3), respectively. Additionally, the high-fat diet-fed rat model showed more pain-like behavior than the lean model.</p><p><strong>Main conclusion: </strong>These studies indicate that weight loss could decrease OA pain in both target and nontarget knees of patients with obesity, supporting the inclusion of obesity in OA animal models to improve the translatability of OA treatments.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 11","pages":"bvag245"},"PeriodicalIF":4.4,"publicationDate":"2026-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rosa Di Paola, Claudia Menzaghi, Mario Mastroianno, Monia Garofolo, Lucia Salvemini, Daniela Lucchesi, Salvatore De Cosmo, Giuseppe Penno, Philippe Froguel, Alessandro Doria, Vincenzo Trischitta
{"title":"All-cause mortality in people with type 2 diabetes and lipodystrophy-like metabolic phenotype.","authors":"Rosa Di Paola, Claudia Menzaghi, Mario Mastroianno, Monia Garofolo, Lucia Salvemini, Daniela Lucchesi, Salvatore De Cosmo, Giuseppe Penno, Philippe Froguel, Alessandro Doria, Vincenzo Trischitta","doi":"10.1210/jendso/bvag238","DOIUrl":"https://doi.org/10.1210/jendso/bvag238","url":null,"abstract":"<p><strong>Aim: </strong>We wanted to investigate whether the lipodystrophy (LD)-like phenotype increases mortality in type 2 diabetes. To this end we first developed and confirmed the triglyceride/BMI ratio (TBR index) as an inexpensive and widely available marker of the LD-like metabolic phenotype. The TBR index was then tested for association with all-cause mortality in patients with type 2 diabetes.</p><p><strong>Research design and methods: </strong>Associations between TBR and mortality were assessed by Cox in 3 type 2 diabetes cohorts (n = 2137, n = 960, and n = 5060). A 20-SNP genotype risk score (GRS), associated with LD-like phenotype was investigated to identify the molecular basis of TBR variability.</p><p><strong>Main finding: </strong>In all cohorts, the highest TBR decile showed features of LD-like phenotype, including atherogenic dyslipidemia, lower BMI, worse glycemic control, insulin resistance, elevated gamma-glutamyl transferase, and hypoadiponectinemia. In the meta-analysis, decile 10 had higher mortality risk (HR = 1.46, <i>P</i> < .0001). Finally, in a subset of 1 of the 3 cohorts, the LD-like GRS was significantly associated with TBR.</p><p><strong>Conclusion: </strong>The TBR is a novel, inexpensive and easily available marker that identifies a subgroup of type 2 diabetes patients with a LD-like phenotype, partly explained by genetic factors. Our findings help disentangle the heterogeneity of death risk in diabetes, refine diagnostic and follow-up algorithms and enable specific treatments for improving long-term outcomes in LD-like individuals.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 11","pages":"bvag238"},"PeriodicalIF":4.4,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13720639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149322554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matías A Belluno, Fabrizio G Arona, Katia E Helfenberger, Martina A Rodrigo, María Mercedes Mori Sequeiros Garcia, Paula M Maloberti, Yanina Benzo, Cecilia Poderoso
{"title":"Angiotensin II and cAMP signaling pathways regulate mitochondrial biogenesis and activity in human adrenocortical cells.","authors":"Matías A Belluno, Fabrizio G Arona, Katia E Helfenberger, Martina A Rodrigo, María Mercedes Mori Sequeiros Garcia, Paula M Maloberti, Yanina Benzo, Cecilia Poderoso","doi":"10.1210/jendso/bvag218","DOIUrl":"https://doi.org/10.1210/jendso/bvag218","url":null,"abstract":"<p><p>Mitochondrial homeostasis, governed by the balance between biogenesis and mitophagy, is essential for steroidogenesis in adrenocortical cells. While the requirement of active mitochondria for steroid synthesis is well-established, the hormonal regulation of genes governing mitochondrial function remains poorly understood. This study investigated whether angiotensin II (Ang II) and the cAMP/PKA pathway modulate the expression of key regulatory factors involved in mitochondrial biogenesis and redox status in the human adrenocortical H295R cell line. Using real-time qPCR and Western blot, we show that Ang II and 8Br-cAMP-a permeant analog of cAMP-modulate NRF-1, Nrf2, UCP2, and ANT1 impacting on mitochondrial biogenesis, antioxidant defense, and respiratory activity. These molecular changes correlated with increased mitochondrial membrane polarization, as confirmed by MitoTracker red staining. Interestingly, Ang II stimulation promoted a time-dependent increase in TFAM levels, a key transcription factor in mitochondria, which correlates with the increase in mitochondrial DNA (mtDNA) content. The rate of oxygen consumption (OCR) and mitochondrial parameters were determined, with results showing that Ang II led to a significant increase in basal and maximum respiration, ATP production, and proton leak. These findings suggest that hormone stimulation favors mitochondrial activity, thereby enhancing the bioenergetic capacity of adrenocortical cells. Furthermore, treatment with the uncoupler CCCP triggered a retrograde signaling response, upregulating nuclear-encoded mitochondrial genes to counteract mitochondrial membrane depolarization. Our findings demonstrate for the first time that hormonal signals directly modulate the mitochondrial genetic program in H295R human adrenocortical cells, optimizing the bioenergetic platform required for efficient steroidogenic function.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 10","pages":"bvag218"},"PeriodicalIF":4.4,"publicationDate":"2026-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635867/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Endocrine complications of COVID-19: diabetes, musculoskeletal, thyroid, pituitary, adrenal, and gonadal disorders.","authors":"Kamyar Asadipooya, Srividya Sriramula","doi":"10.1210/jendso/bvag219","DOIUrl":"https://doi.org/10.1210/jendso/bvag219","url":null,"abstract":"<p><p>COVID-19 is generally associated with both short- and long-term complications. It can affect multiple organ systems and lead to severe or prolonged organ dysfunction, including the endocrine system. It also places a substantial burden on individuals and the health-care system. Therefore, providing up-to-date information for health-care providers is valuable. In this review, we aim to consolidate the current literature regarding the endocrine complications of acute SARS-CoV-2 infection, with a particular focus on diabetes, calcium homeostasis, pituitary, thyroid, adrenal, and gonadal disorders. Although current therapeutic approaches for COVID-19 are mainly limited to antivirals, symptomatic therapies, and supportive care, advances in understanding the mechanisms of SARS-CoV-2 entry and immune responses may support a more effective and personalized approach to clinical care.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 10","pages":"bvag219"},"PeriodicalIF":4.4,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yaanu Jeyakumar, Ravi Retnakaran, Denice S Feig, Bernard Zinman, Caroline K Kramer
{"title":"The effect of time-restricted eating accompanied by weight loss on thyroid function in adults with type 2 diabetes.","authors":"Yaanu Jeyakumar, Ravi Retnakaran, Denice S Feig, Bernard Zinman, Caroline K Kramer","doi":"10.1210/jendso/bvag216","DOIUrl":"https://doi.org/10.1210/jendso/bvag216","url":null,"abstract":"<p><strong>Context: </strong>Time-restricted eating (TRE) is a lifestyle intervention associated with beneficial cardiometabolic effects. The impact of TRE-induced weight reduction on thyroid hormonal responses is not well elucidated.</p><p><strong>Objective: </strong>To evaluate the effects of TRE accompanied by weight loss on thyroid function in adults with obesity and type 2 diabetes (T2DM).</p><p><strong>Methods: </strong>We performed an exploratory analysis of a randomized, crossover, open-label study in adults with obesity and T2DM who underwent 2 dietary interventions: TRE and standard lifestyle. Each intervention period lasted 6 weeks. Thyroid function was assessed by TSH, free T4 (fT4), free T3 (fT3), and reverse T3 (rT3).</p><p><strong>Results: </strong>Thirty-nine participants without known thyroid disease (age 56.3 years, 35.9% male, body mass index 32.4 ± 5.7 kg/m<sup>2</sup>) were included. TRE induced significant weight loss (-2.93 kg) compared to the standard lifestyle period (0.59 kg) (mean differences between intervention periods of -3.50 kg ± 2.9; <i>P</i> < .001). Despite this robust weight-lowering effect, there were no significant differences in TSH (0.49 mUI/L ± 3.0; <i>P</i> = .32), fT3 (-0.57 pmol/L ± 2.7; <i>P</i> = .19), fT4 (fT4 -0.55 pmol/L ± 3.8; <i>P</i> = .38), and rT3 (-0.94 ng/dL ± 5.9; <i>P</i> = .350) between intervention periods. Reinforcing these findings, there was no treatment effect interaction on any thyroid function test evaluated. In addition, there was no significant change in the fT3: fT4 and fT3:rT3 ratios between treatment interventions.</p><p><strong>Conclusion: </strong>Despite inducing significant weight loss, TRE did not exert a significant effect on thyroid function in individuals with obesity and early T2DM.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 10","pages":"bvag216"},"PeriodicalIF":4.4,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13624272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clara O Sailer, Francesca Galbiati, Anna Aulinas, Maged Muhammed, Regine Boutin, Jenna Bourassa, Cihan Atila, Julia Crowley, Allie Dayno, Hannah Pearlstein, Lisa B Nachtigall, Karen K Miller, Nicholas A Tritos, Ursula B Kaiser, Shana E McCormack, Mirjam Christ-Crain, Laura E Dichtel, Elizabeth A Lawson
{"title":"Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study.","authors":"Clara O Sailer, Francesca Galbiati, Anna Aulinas, Maged Muhammed, Regine Boutin, Jenna Bourassa, Cihan Atila, Julia Crowley, Allie Dayno, Hannah Pearlstein, Lisa B Nachtigall, Karen K Miller, Nicholas A Tritos, Ursula B Kaiser, Shana E McCormack, Mirjam Christ-Crain, Laura E Dichtel, Elizabeth A Lawson","doi":"10.1210/jendso/bvag211","DOIUrl":"10.1210/jendso/bvag211","url":null,"abstract":"<p><strong>Context: </strong>Arginine vasopressin deficiency (AVP-D), caused by hypothalamic/pituitary damage from tumor or surgery, can be transient or chronic. Chronic AVP-D is thought to be permanent though emergent research indicates the possibility of late recovery. Little is known about clinical characteristics that predict late recovery from chronic AVP-D.</p><p><strong>Objective: </strong>Describe characteristics associated with late recovery from chronic AVP-D.</p><p><strong>Design: </strong>Multicenter, retrospective case-control study of AVP-D Recovered (n = 18) vs AVP-D Non-recovered (n = 36; matched for sex and disease duration).</p><p><strong>Main outcome measures: </strong>Clinical characteristics assessed at hypothalamic/pituitary disease diagnosis, AVP-D diagnosis, AVP-D recovery, and most recent clinical evaluation. We also present characteristics of three pediatric cases with AVP-D recovery.</p><p><strong>Results: </strong>At diagnosis of hypothalamic/pituitary disease, AVP-D Recovered, compared to AVP-D Non-recovered, were older (45 ± 19 vs 33 ± 13 years, <i>P</i> = .006) and more likely to have functioning pituitary tumors (33.3% vs 8.3%, <i>P</i> = .05). Following diagnosis of AVP-D, AVP-D Recovered received lower total daily doses of desmopressin (100 [IQR; 50, 100] vs 200 [100, 200] µg oral or equivalent, <i>P</i> = .01). Recovery occurred after a median of 6.3 years [1.7, 12.0] and occurred earlier in those without hypothyroidism (<i>P</i> = .049) or adrenal insufficiency at diagnosis of AVP-D (<i>P</i> = .008).</p><p><strong>Conclusion: </strong>Our study supports the notion that chronic AVP-D may not be permanent across the lifespan. Continued requirement for desmopressin, particularly in those with a history of functioning pituitary tumors, low doses of desmopressin, and without concurrent hypothyroidism or adrenal insufficiency at diagnosis, should be regularly reassessed.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 10","pages":"bvag211"},"PeriodicalIF":4.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah F Schlegel, Jessica Kremen, Alayna Dutcher, Stacey Pereira, Ingrid A Holm, Yee-Ming Chan
{"title":"Parental anxiety in differences of sex development and hypospadias: a psychosocial characterization.","authors":"Sarah F Schlegel, Jessica Kremen, Alayna Dutcher, Stacey Pereira, Ingrid A Holm, Yee-Ming Chan","doi":"10.1210/jendso/bvag212","DOIUrl":"10.1210/jendso/bvag212","url":null,"abstract":"<p><strong>Context: </strong>Parents of children with differences of sex development (DSD) and hypospadias experience significant psychological distress, but the factors contributing to parental anxiety remain poorly understood.</p><p><strong>Objective: </strong>Identify psychosocial factors associated with anxiety among parents of children with urogenital conditions and compare anxiety levels to parents in other pediatric settings.</p><p><strong>Design: </strong>Cross-sectional survey study.</p><p><strong>Setting: </strong>Pediatric subspecialty clinics at an academic medical center.</p><p><strong>Participants: </strong>One hundred and eight parents of children with urogenital conditions without established genetic diagnoses, compared with 346 parents from BabySeq, a newborn genomic sequencing trial (278 parents of healthy newborns, 68 parents of neonatal intensive care unit [NICU] infants).</p><p><strong>Main outcome measures: </strong>Anxiety symptoms (Generalized Anxiety Disorder 7-item scale [GAD-7]), stigma, and quality of life.</p><p><strong>Results: </strong>Clinically significant anxiety (GAD-7 ≥ 5) was present in 33% of parents of children with urogenital conditions, similar to the rate in parents of NICU infants (34%) and significantly higher than in parents of healthy newborns (21%, <i>P</i> = .03). Forty-one percent reported self-blame for their child's condition; 16% reported blaming their partners. Quality of life decreased with increasing stigma (<i>P</i> = .001), genital atypicality (<i>P</i> = .03), and anxiety scores (<i>P</i> = .04). Backward elimination and Least Absolute Shrinkage and Selection Operator regression with multiple imputation identified 4 key factors predicting increased anxiety: higher intolerance of uncertainty, increased parental health-related stress, lower educational level, and greater emotional stigma. Additional factors included greater genital atypicality, social isolation, and self-blame.</p><p><strong>Conclusion: </strong>Parents of children with urogenital conditions experience anxiety levels comparable to parents of infants in the NICU, despite their children being medically stable. Uncertainty intolerance and emotional stigma provide targets for clinical screening and early intervention.</p>","PeriodicalId":17334,"journal":{"name":"Journal of the Endocrine Society","volume":"10 10","pages":"bvag212"},"PeriodicalIF":4.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13621186/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149081483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}